Nanogroup SA - Asset Resilience Ratio
Nanogroup SA (NNG) has an Asset Resilience Ratio of 7.66% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Nanogroup SA strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Nanogroup SA's Asset Resilience Ratio has changed over time. See NNG net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Nanogroup SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nanogroup SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł1.27 Million | 7.66% |
| Total Liquid Assets | zł1.27 Million | 7.66% |
Asset Resilience Insights
- Limited Liquidity: Nanogroup SA maintains only 7.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nanogroup SA Industry Peers by Asset Resilience Ratio
Compare Nanogroup SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Nanogroup SA (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Nanogroup SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.36% | zł1.27 Million ≈ $348.83K |
zł19.94 Million ≈ $5.49 Million |
-1.73pp |
| 2022-12-31 | 8.09% | zł1.55 Million ≈ $427.55K |
zł19.20 Million ≈ $5.28 Million |
+7.70pp |
| 2019-12-31 | 0.39% | zł102.20K ≈ $28.13K |
zł26.38 Million ≈ $7.26 Million |
-- |
About Nanogroup SA
NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology. The company was incorporated in 2016 and is based in Warsaw, Poland.